Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/56749
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMartín-Rivada, Álvaro-
dc.contributor.authorBarrios, Vicente-
dc.contributor.authorMartínez Díaz-Guerra, Guillermo-
dc.contributor.authorPozo, Jesús-
dc.contributor.authorMartos-Moreno, Gabriel Ángel-
dc.contributor.authorArgente, Jesús-
dc.date.accessioned2022-12-22T13:30:01Z-
dc.date.available2022-12-22T13:30:01Z-
dc.date.issued2021-07-25-
dc.identifier.citationGrowth Horm IGF Res.2021;(60-61):101419-
dc.identifier.urihttps://hdl.handle.net/20.500.12530/56749-
dc.description.abstractPAPP-A2 deficiency is a novel syndrome characterized by short stature due to low IGF bioactivity, skeletal abnormalities and decreased bone mineral density (BMD). Treatment with recombinant human IGF-1 (rhIGF-1) for 1 year demonstrated to increase growth velocity and BMD, without reported adverse effects, but data regarding the long-term efficacy and safety of rhIGF-1 administration in this entity has not yet been reported. Two Spanish siblings with short stature due to a homozygous loss-of-function mutation in the PAPP-A2 gene (p.D643fs25*) were treated with rhIGF-1 twice daily for six years. Growth velocity continued to increase and both patients achieved their target height. Free IGF-1 concentrations increased notably after rhIGF-1 administration, with serum IGFBP-3, IGFBP-5 and ALS levels also being higher during treatment. BMD was progressively normalized and an increase in lean mass was also noted during treatment. No episodes of hypoglycemia or any other adverse effects were documented. An increase in the growth of kidney and spleen length was observed in one of the patients.-
dc.language.isoen-
dc.rightsOpen Access-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/-
dc.subjectBone density-
dc.subjectFree IGF-1-
dc.subjectGH/IGF-1-
dc.subjectGrowth-
dc.subjectPAPP-A2-
dc.subjectTotal IGF-1-
dc.subjectrhIGF-1-
dc.subject.meshBody Height-
dc.subject.meshChild-
dc.subject.meshFemale-
dc.subject.meshFollow-Up Studies-
dc.subject.meshGrowth Disorders-
dc.subject.meshHuman Growth Hormone-
dc.subject.meshHumans-
dc.subject.meshInsulin-Like Growth Factor Binding Protein 3-
dc.subject.meshInsulin-Like Growth Factor I-
dc.subject.meshMale-
dc.subject.meshPregnancy-Associated Plasma Protein-A-
dc.subject.meshPrognosis-
dc.subject.meshRecombinant Proteins-
dc.titleAdult height and long-term outcomes after rhIGF-1 therapy in two patients with PAPP-A2 deficiency.-
dc.typeArtículo-
dc.identifier.pubmedID34358737-
dc.format.volume60-61-
dc.format.page101419-
dc.identifier.e-issn1532-2238-
dc.identifier.journalGrowth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society-
dc.identifier.journalabbreviationGrowth Horm IGF Res-
dc.identifier.doi10.1016/j.ghir.2021.101419-
dc.pubmedtypeCase Reports-
dc.pubmedtypeJournal Article-
dc.pubmedtypeResearch Support, Non-U.S. Gov't-
Appears in Collections:Fundaciones e Institutos de Investigación > FIB H. Infantil U. Niño Jesús > Artículos
Hospitales > H. U. 12 de Octubre > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. La Princesa > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. 12 de Octubre > Artículos

Files in This Item:
File SizeFormat 
34358737.pdf2.19 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons